Kopetz, Scott

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 166

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research

Colorectal Cancer Treatments and StudiesCancer Mechanisms and Therapy

Cited by 160

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation

HER2/EGFR in Cancer ResearchCancer-related gene regulation

Cited by 155

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 139

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 135

Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer

Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 132

Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer

Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 132

Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression

Hsu, W.-H., LaBella, K. A., Lin, Y., Xu, P., Lee, R., Hsieh, C.-E., Yang, L., Zhou, A., Blecher, J. M., Wu, C.-J., et al. (2023) · Cancer Discovery

Cancer Cells and MetastasisAngiogenesis and VEGF in Cancer

Cited by 125

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 123

Src continues aging: current and future clinical directions

Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research

Cancer Mechanisms and TherapyProtein Kinase Regulation and GTPase Signaling

Cited by 111

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

Association between KRAS mutation and lung metastasis in advanced colorectal cancer

Pereira, A. A. L., Rego, J. F. M., Morris, V, Overman, M. J., Eng, C., Garrett, C. R., Boutin, A. T., Ferrarotto, R., Lee, M., Jiang, Z.-Q., et al. (2015) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 94

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics

Cited by 82

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., et al. (2024) · Nature Cancer

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 76

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors

Riedl, J. M., Fece de la Cruz, F., Lin, J. J., Parseghian, C., Kim, J. E., Matsubara, H., Barnes, H., Caughey, B., Norden, B. L., Morales-Giron, A. A., et al. (2025) · Annals of Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 68

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer

Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 68

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 67

Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer

Henry, J. T., Coker, O., Chowdhury, S., Shen, J. P., Morris, V. K., Dasari, A., Raghav, K., Nusrat, M., Kee, B., Parseghian, C., et al. (2021) · JCO Precision Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 66

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., et al. (2022) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 62

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

Kopetz, S., McDonough, S. L., Lenz, H.-J., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Raghav, K. P. S., Morris, V. K., Wang, S. E., et al. (2017) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 58

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2

Chang, K., Willis, J. A., Reumers, J., Taggart, M. W., San Lucas, F. A., Thirumurthi, S., Kanth, P., Delker, D. A., Hagedorn, C. H., Lynch, P. M., et al. (2018) · Annals of Oncology

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 51

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

Fakih, M., Tu, H., Hsu, H., Aggarwal, S., Chan, E., Rehn, M., Chia, V., & Kopetz, S. (2022) · The Oncologist

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 43

Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer

Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 43

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., et al. (2019) · Journal of Experimental & Clinical Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 40